Xinnate is a startup based in Sweden, most recent round Series A, 1 tracked investor.
Xinnate is a company founded in 2018 headquartered in Sweden. Its most recent tracked round is Series A. Brouky records 1 investor associated with the company.
Xinnate is a clinical-stage pharmaceutical company developing next-generation therapies built on proprietary peptide technology designed to restore balance in dysfunctional wound healing, particularly for Epidermolysis Bullosa and other inflammatory skin disorders.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.